All the great news this year related to hair loss research, trials and potential cures has made people (including myself) very optimistic. However, a lot of hair loss sufferers are becoming excessively passionate about a select few companies (especially Histogen and Replicel) or about the results from a select few clinical trials. I therefore decided to write this post as a warning from past experiences of putting too much faith into any one or two entities. Something as simple as lack of sufficient funding despite successful stage 2 clinical trials can cause a company to stop pursuing highly promising products.
In the mid-to-late 2000s, two companies named Aderans (Japan) and Intercytex (UK) caused tremendous excitement in all the online hair loss forums. Both were involved in groundbreaking research related to hair cloning and hair multiplication. Moreover, Aderans’ research was led by the renowned Dr. Ken Washenik through the Aderans Research Institute, and he made numerous presentations about their technology at various conferences. Below are two of those:
However, in 2013, Aderans decided to liquidate its research institute. Spencer Kobren had a segment about this on his usually weekly radio show:
Intercytex abandoned its work in 2010 due to financial difficulties, despite positive results from phase 1 trials. According to the company’s website, “the Intercytex name and ICX-RHY were purchased by private investors and relaunched as Intercytex Ltd in 2010”. ICX-RHY is a skin repair product.
As of 2014, Aderans’ research is focused on wigs and hair replacement (they purchased US-based hair restoration market leading companies Hair Club in 2013 and Bosley in 2001), while Intercytex’s research is focused on products that tackle skin problems.